MacroGenics Inc. (Nasdaq: MGNX) licensed its preclinical biospecifc molecule MGD015 to Janssen Biotech. Shares of the biopharmaceutical leaped $3.02 to close at $21.06.
MacroGenics licenses MGD015
May 18, 2016 at 18:15 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.